PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
April 5, 2026Cancer Research0 citations

Abstract 2997: LTA4H promotes intrahepatic cholangiocarcinoma progression via mTOR activation and T-cell exhaustion

View Full Paper
GLG. Sharat LinWenzhou Medical UniversityJWJinhui WangWenzhou Medical UniversityYHY. Thomas HeSun Yat-sen University

Key Points

  • The research aims to investigate the role of LTA4H in promoting intrahepatic cholangiocarcinoma and its underlying mechanisms.
  • Assessed LTA4H expression and prognostic significance in ICC cohorts and cell lines using various techniques.
  • Genetically modified LTA4H levels in ICC cell lines to evaluate functional impacts.
  • Modeled spontaneous ICC in mice through plasmid injection to study tumor progression.
  • Investigation of the tumor immune environment through flow cytometry and mechanistic insights via RNA sequencing.
  • Tested the therapeutic efficacy of LTA4H-specific inhibitor LYS006 in vivo and in organoids.
  • LTA4H was overexpressed in ICC tissues and linked to poorer patient outcomes.
  • Overexpression of LTA4H accelerated ICC cell growth, migration, and tumor growth in mice.
  • Knockdown of LTA4H inhibited malignant behaviors in ICC cells.
  • LTA4H was found to activate the mTOR pathway and cause T-cell exhaustion.
  • Therapeutic inhibition of LTA4H with LYS006 led to significant tumor growth suppression.

Abstract

Abstract Introduction: Intrahepatic cholangiocarcinoma (ICC) is a highly aggressive liver cancer with a poor prognosis. Immune evasion plays a critical role in ICC progression. Leukotriene A4 hydrolase (LTA4H), a key enzyme in eicosanoid metabolism, is overexpressed in multiple cancer types; however, its role and mechanism in ICC remain entirely unexplored. Methods: LTA4H expression and its prognostic significance were assessed in two independent ICC cohorts (n=130) and cell lines using bioinformatics, immunohistochemistry (IHC), and western blot (WB). LTA4H was genetically modulated in ICC cell lines via lentiviral transduction. Functional impacts on proliferation, migration, and invasion were evaluated by colony formation, real-time cellular analysis, wound healing, and Transwell assays. Spontaneous ICC was modeled in mice via hydrodynamic tail vein injection of a plasmid combination comprising pT3-EF1α-myr-AKT, pT3-EF1α-myr-NICD, and pCMV-SB. Mechanistic insights were investigated through RNA sequencing, metabolomics, and WB. Tumor immune microenvironment was profiled by flow cytometry. The therapeutic efficacy of the LTA4H-specific inhibitor LYS006 was tested in vivo and in patient-derived organoids. Results: LTA4H was significantly overexpressed in ICC tissues and correlated with poor patient survival. LTA4H overexpression enhanced ICC cell proliferation, migration, and invasion in vitro, and accelerated tumor progression in vivo. Conversely, LTA4H knockdown suppressed these malignant phenotypes. Mechanistically, LTA4H activated the mTOR signaling pathway and induced T-cell exhaustion in the tumor microenvironment. Therapeutic inhibition of LTA4H with LYS006 significantly suppressed tumor growth in mouse models and organoids. Conclusions: Our study identifies LTA4H as a novel oncoprotein in ICC that drives tumor progression by activating the mTOR pathway and fostering an immunosuppressive microenvironment via T-cell exhaustion. Targeting LTA4H represents a promising therapeutic strategy for ICC. Clinical Significance: This work unveils the dual pro-tumorigenic functions of LTA4H in ICC and provides a strong rationale for targeting LTA4H, potentially alone or in combination with immunotherapy, for the treatment of this lethal disease. Citation Format: Ganglian Lin, Jinhui Wang, Yizhuo He, Fangkai Feng, Chongming Zheng, Yi Wang. LTA4H promotes intrahepatic cholangiocarcinoma progression via mTOR activation and T-cell exhaustion abstract. In: Proceedings of the American Association for Cancer Research Annual Meeting 2026; Part 1 (Regular Abstracts); 2026 Apr 17-22; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2026;86(7 Suppl):Abstract nr 2997.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Lin et al. (2026) studied this question.

synapsesocial.com/papers/69d1fcd4a79560c99a0a2773https://doi.org/10.1158/1538-7445.am2026-2997
Ask AI
Helpful
Bookmark
Share
View Full Paper

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Abstract 2694: The role of innate lymphoid cells and innate like T cells in hepatocellular carcinoma2024
  2. 2Oncogenic LPCAT1 Accelerates Intrahepatic Cholangiocarcinoma Development Through PI3K/Akt Signaling‐Dependent Cell Cycle Regulation2026
  3. 3Abstract 7407: The NAT10-PBX1 ac4C axis disables MHC Class II antigen presentation to promote immune-cold cholangiocarcinoma2026
  4. 4Abstract 1585: Kinetic profiling of ILC and ILTC responses during early hepatocellular carcinoma development reveals IL-15-ILC1 axis2026
  5. 5Expression and clinical significance of LTA4H in esophageal squamous cell carcinoma2026